Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib versus nilotinib in newly diagnosed Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia
2007-000208-34Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic myelogenous leukemia (CML) comparing Nilotinib with Imatinib (2 arms). Primary endpoint: Major molecular response at 12 months. Started Mar 2007; status: completed.
02
Drugs
nilotinibimatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2007-000208-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000208-34.